Sunday, 06/04/2006 2:00 PM - 6:00 PM Phase I study of trabectedin (T) in combination with docetaxel (D) in patients with advanced malignancies.Poster Number: C9 Abstract No: 2068 Presenter:Margaret Von Mehren
Sunday, 06/04/2006 2:00 PM - 6:00 PM Phase I and pharmacokinetics (PK) study of sequential paclitaxel and trabectedin every 2 weeks in patients with advanced solid tumors.Poster Number: 19 Abstract No: 2029 Presenter:Kyriakos Peter Papadopoulos, MD
Sunday, 06/04/2006 2:00 PM - 6:00 PM Phase I clinical and pharmacological trial of trabectedin (T) in 3 hour infusion every 3 weeks (3h/q3w) in patients with advanced cancer and hepatic function disorder.Poster Number: D9 Abstract No: 2080 Presenter:Ramon Salazar
Sunday, 06/04/2006 9:00 AM - 1:00 PM DNA repair functionality modulates the clinical outcome of patients with advanced sarcoma treated with trabectedin (ET-743).Poster Number: 8 Abstract No: 9522 Presenter:Patrick Schöffski, MD, MPH
Sunday, 06/04/2006 8:00 AM - 12:00 PM Phase II open label randomized study of trabectedin (T) given as two different dosing schedules in women with platinum-sensitive, recurrent ovarian carcinoma: Preliminary results.Poster Number: 23 Abstract No: 5031 Presenter:Jm Del Campo
Sunday, 06/04/2006 2:00 PM - 6:00 PM Population pharmacokinetics of trabectedin (ET-743) in subjects with cancer.Poster Number: 20 Abstract No: 2030 Presenter:Juan J Perez Ruixo
Sunday, 06/04/2006 2:00 PM - 6:00 PM Phase I combination study of trabectedin (T) and capecitabine (C) in patients with advanced malignancies.Poster Number: D8 Abstract No: 2079 Presenter:Lia Gore
Monday, 06/05/2006 1:00 PM - 5:00 PM Semi-physiological pharmacokinetic/pharmacodynamic (PKPD) model for trabectedin-induced neutropenia.Poster Number: M3 Abstract No: 9575 Presenter:Jeremy Hing
Saturday, 06/03/2006 4:15 PM - 4:30 PM Patterns of tumor response to trabectedin (ET743) in myxoid liposarcomas.Abstract No: 9511 Presenter:Federica Grosso, MD
Monday, 06/05/2006 1:00 PM - 5:00 PM Assessment of trabectedin (T) induced liver toxicity with correlation to liver morphology in a phase I study of T + pegylated liposomal doxorubicin (PLD).Poster Number: L3 Abstract No: 9568 Presenter:Antoine Yver
Sunday, 06/04/2006
2:00 PM - 6:00 PM Preliminary data of a phase I-II clinical and pharmacokinetic study of plitidepsin in children with malignant tumors. On behalf of the European ITCC (Innovative Therapies for Children with Cancer) Consortium.
Poster Number: V11 Abstract No: 9060 Presenter:
Birgit Geoerger Pediatric Cancer Details ... Bldg B, Level 1, Hall B5